AbbVie partners with Valkai to put AI into clinical development workflows
AbbVie said Tuesday it is partnering with Valkai, a life-sciences AI platform, to deploy purpose-built AI across targeted areas of clinical research so teams can generate insights faster and look for chances to shorten development timelines.
Clinical trial teams already sit on more data than a person can coordinate by hand. AbbVie is plugging a life-sciences AI layer into that work so people can spend more time on the science and less on the handoffs.
On Tuesday, 29 September 2026, AbbVie (NYSE: ABBV) said it is starting a new collaboration with Valkai to strengthen integrated AI capabilities across clinical development. AbbVie is the drug company whose stock trades on the New York Stock Exchange under ABBV. Clinical development is the work of testing a medicine in people and turning that evidence into the next decision. The newsroom page is dated September 29, 2026. PR Newswire carries the same release and prints Sep 29, 2026, 09:00 ET, which is 9:00 a.m. Eastern. The dateline is North Chicago, Illinois. Those pages are AbbVie’s.
Valkai, in the release, is a life-sciences AI platform built to help scientific work reach patients faster. Through the partnership, AbbVie will deploy purpose-built AI across targeted areas of clinical research. Purpose-built, here, means the tools are made for those jobs, not a general chatbot dropped on the whole company. AbbVie says the aim is to improve efficiency, help teams generate insights more quickly, and support opportunities to reduce development timelines. That “reduce” is a chance the company names. The release does not print a number of months saved, a dollar figure for the deal, a promise that no other drugmaker can use Valkai, or a named drug this work will touch.
AbbVie says artificial intelligence already plays a role in how medicines are discovered, developed, and delivered, and that the Valkai partnership builds on AI work the company already does across research and development. Research and development, often shortened to R&D, is the path from the lab to the trials that come before a medicine is widely available. The release says the partnership is meant to scale data-driven insights on that foundation.
Nicholas Donoghoe, executive vice president and chief business and strategy officer at AbbVie, said the company is focused on applying AI where it can create meaningful impact for the business and, ultimately, for patients. He said clinical data keeps growing in volume and complexity, and that partnerships like Valkai help generate insights faster so teams can spend more time on the decisions that matter most. He said combining advanced AI with human expertise can help bring new medicines to patients more efficiently. That quotation is his, in the release.
Andrew Campbell, M.D., vice president of clinical sciences at AbbVie, said success in that group depends on learning quickly, adapting, and making confident decisions from a growing body of evidence. He said AI capabilities like Valkai have the potential to reduce time spent on manual processes and leave more attention for scientific interpretation and clinical strategy, and for the insights that can advance medicines for patients. Manual processes, in his sentence, are the hand steps between the data and the scientific call. That quotation is his, in the release.
Vignesh Rajendran, co-founder and chief executive of Valkai, said the company is delighted to partner with AbbVie, combining advanced AI capabilities with deep scientific expertise. He said AbbVie’s scale, its innovation, and its focus on patients make this the kind of partnership that can turn ambition into impact. That quotation is his, in the release.
The about-Valkai block in the same release calls Valkai the AI operating system for life sciences. An operating system, in that phrase, is Valkai’s name for a layer across the work, not the software that starts a laptop. The block says the mission is to significantly accelerate time to market for critical medicines, and that global Fortune 500 pharma and medtech leaders partner with Valkai so decisions can be faster and smarter. Fortune 500 means the largest companies on that magazine’s list. Medtech is medical devices and the tools around them. The team, the block says, comes from research and applied AI companies such as OpenAI, Google DeepMind, Sierra, and Glean. Those lines are AbbVie’s description of Valkai. They are not a price for this partnership, and they are not a list of medicines it will cover.
AbbVie places the partnership under AI@AbbVie, its name for using artificial intelligence across the company. The release says that approach is meant to advance scientific innovation, strengthen business results, and improve how medicines are discovered, developed, and delivered. It says AI helps employees with productivity and decisions across R&D, operations, and other core work, guided by human expertise and responsible governance. The same page says AI is there to complement what employees already see, while the company keeps a commitment to responsible and ethical use.
In plain terms, AbbVie said on Tuesday it will put Valkai’s tools into targeted parts of clinical research so teams can pull insights out of growing trial data faster and look for ways to shorten development. The people named are Donoghoe, Campbell, and Rajendran. The pages do not say what the deal costs, whether anyone else is shut out, which drugs are in scope, or how many months a program will save.
The picture is a desk graphic of that workflow. A cream card carries burgundy type and a teal clinical board. Three steps run across it: clinical trial data, Valkai agents, and AbbVie research and development. A strip along the bottom is Valkai’s banner, “Now partnering with AbbVie,” with the line “Agent systems for life sciences.” It is a diagram of the partnership in the release. It is not a screenshot of a product screen from the wire.